Randall Stanicky
Stock Analyst at RBC Capital
(2.37)
# 2,302
Out of 4,820 analysts
32
Total ratings
60%
Success rate
5.18%
Average return
Main Sectors:
Stocks Rated by Randall Stanicky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $180.37 | -25.15% | 10 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | $59 → $49 | $24.89 | +96.87% | 8 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | $43 → $42 | $22.78 | +84.37% | 3 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $170 → $180 | $108.98 | +65.17% | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | $92 → $89 | $79.84 | +11.47% | 1 | Apr 1, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | $3 → $4 | $7.42 | -46.09% | 3 | Jan 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | $495 | $9.26 | +5,245.57% | 1 | Nov 7, 2017 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Underperform | n/a | $14.72 | - | 3 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $58 | $26.00 | +123.08% | 1 | Apr 13, 2017 |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $180.37
Upside: -25.15%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: $59 → $49
Current: $24.89
Upside: +96.87%
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: $43 → $42
Current: $22.78
Upside: +84.37%
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: $170 → $180
Current: $108.98
Upside: +65.17%
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: $92 → $89
Current: $79.84
Upside: +11.47%
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: $3 → $4
Current: $7.42
Upside: -46.09%
OptiNose
Nov 7, 2017
Initiates: Outperform
Price Target: $495
Current: $9.26
Upside: +5,245.57%
Teva Pharmaceutical Industries
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $14.72
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: $58
Current: $26.00
Upside: +123.08%